|
New York, 12/06/2023 / 08:00, EST/EDT – EQS Newswire – Laxxon Medical NEW YORK, NY / ACCESSWIRE / December 6, 2023 / Laxxon Medical announced today its attendance at the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California. The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, connecting global industry leaders, emerging fast-growth companies and innovative technologies of the investment community. Representing Laxxon Medical at the J.P.Morgan Healthcare Conference is CEO Helmut Kerschbaumer and Chief Strategy Officer Alexander Ruckdaeschel, who will meet with institutional investors. About Laxxon Medical Laxxon’s pipeline includes ongoing working-projects with notable pharma players, biotech companies and research universities, in addition to 13 in-house Advanced Patented Generics products. Laxxon’s IP is continuously growing and consists of 150 patents and patent applications with more than 3,000 patent claims. Laxxon is partnered with CDMO Hovione and is jointly establishing cGMP productions in Portugal and the United States. Company website: www.laxxonmedical.com. Company Contact SOURCE: Laxxon Medical 12/06/2023 EQS Newswire / EQS Group AG |
Could billions of dollars in AI funding lead to the same number of new drugs?
Drug discovery has quickly become the most enticing place to apply artificial intelligence. Billions of dollars are being invested in AI-driven “techbios.” In an industry
June 25, 2024